Abstracts tagged "Cancer treatments and rituximab"

Abstract Number: 1313 • 2012 ACR/ARHP Annual Meeting
Tolerance of Rituximab in Patients with a History of Cancer : Data From the Registry Air
Jacques-Eric Gottenberg¹, Marie-Odile Duzanski², Thomas Bardin³, Patrice Cacoub⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Bertrand Godeau⁹, Loic Guillevin¹⁰, Eric Hachulla¹¹, Xavier Le Loet¹², Thierry Schaeverbeke¹³, Jean Sibilia¹⁴, Isabelle Pane¹⁵, Philippe Ravaud¹⁶, Gabriel Baron¹⁷ and Xavier Mariette¹⁸, ¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Service Pharmacie - Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³Rheumatology, Hôpital Lariboisière, Paris, France, ⁴Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁵Dept of Rheumatology, Hopital Purpan, Toulouse CEDEX 9, France, ⁶Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁷Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁸Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁹Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹¹Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹²Rheumatology Department, CHU de ROUEN, Rouen, France, ¹³Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁴Rheumatology, CHU Hautepierre, Strasbourg, France, ¹⁵Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁶Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁷Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, ¹⁸Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Data regarding tolerance of biologics in patients with a history of cancer are very limited. We therefore analyzed tolerance of rituximab (RTX) in patients…